DailyIQ
|
DailyIQ
|
Last updatedjust now

CLBT·Cellebrite DI Ltd.

$12.41
+0.03 (+0.24%)
High
$12.90
Open
$12.34
Market Cap
3.11B
52W High
$19.98
Low
$12.14
P. Close
$12.41
P/E
52.96
52W Low
$9.58
Fwd P/E
18.95
DailyIQ Est.
$16.25
Inst. Own.
9.0%
Short Interest
2.87%
Days to Cover
3.8
Technical Score (1D)
9
BEARISH
News Sentiment
54
MIXED
On Nov 5, Cellebrite announced the appointment of Rogerio Rizzi as executive vice president of Corporate Strategy and Development. Rizzi, who had spent more than two decades at Okta, was expected to build out the company’s strategy and development capabilities. The move was seen as a signal that Cellebrite intends to accelerate expansion and deepen its AI‑powered digital investigative offerings. Rizzi’s background in steering Okta to $3 billion in ARR suggested a focus on scalable growth and strategic partnerships. The appointment was viewed as a positive step toward enhancing Cellebrite’s competitive positioning in the public and private sectors.
LOW TARGET
$13 +0.7%
2 analysts
MEAN TARGET
$15 +23.8%
5 analysts
HIGH TARGET
$20 +61.2%
10 analysts
PRICE RANGE
$12.50 - $20.00
SB / B / H / S / SS
4/10/1/1/1
DAILYIQ EST.
$16.25 (+30.9%)
Bought (1Y)
0 shares
$0
Sold (1Y)
196,870 shares
$2.8M
Barter DavidChief Financial Officer
Sell12,134 shares2026-10-16
Ramji ShivenChief Executive Officer
Award/Grant38,505 shares2026-09-24
Domnitz Yonatan-
Award/Grant15,190 shares2026-09-17
Utsumi Ryusuke-
Award/Grant15,190 shares2026-09-17
CLAMMER ADAM-
Award/Grant15,190 shares2026-09-17
View full insider trading history →
85/ 100
Strong bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
84.2%
Net Margin
16.5%
Revenue CAGR
18.5%
Current Ratio
1.56x
Return on Equity
16.2%
View full financials →

EPS

EstBeatMiss
$0.12$0.13$0.15$0.16$0.17Q3'25Q3'26
QtrEstActual+/−
Q3'26$0.16 - -
Q3'25$0.13$0.14+8.5%

Revenue

EstBeatMiss
$123M$130M$137M$145M$152MQ3'25Q3'26
QtrEstActual+/−
Q3'26$149M - -
Q3'25 - $126M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

CLBT Stock Snapshot

BEARISH9/100
$12.41+$0.03 (0.2%)
Market cap
3.11B
P/E ratio
53.0
Day range
$12.14 – $12.90
News sentiment
54/100 · Neutral
Analyst target
$15.36 (+23.8%)
Consensus
Buy · 17 analysts
52-week range+29.5% off low · -37.9% from high
$9.58$19.98
Price $12.41 DailyIQ Est. $16.25

The chart on CLBT has not stabilised: price is in the lower half of its 52-week range and the trend is still down. Company-specific news dominates here; sector-level flows matter less than for larger names.

Behaviour On Record

What CLBT's own history says about today's numbers

Realized volatility (21d)
37.2% 32nd pct
Below its peak
-52.3%
vs 200-day average
-7.4%
Up days (1y)
45%

Cellebrite DI Ltd. is currently running 37.2% annualised volatility over the last 21 sessions. Measured against CLBT's own 6 years of daily returns rather than a market-wide average, that is the 32nd percentile — on the quiet side for this stock, against a typical reading of 45.0%.

CLBT is trading -52.3% below its running peak. Across 6 full years on file, its median worst-drawdown-in-a-year was -41.4%, and the deepest was -51.7% in 2022. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began, and where past declines also continued.

Price sits -7.4% from its 200-day moving average. Against every other day in its history, that gap ranks at the 42nd percentile — close to the gap it normally carries. Over the past year CLBT closed higher on 45% of sessions, and it is currently 1 session into a falling streak.

On November specifically: over 6 years of records, CLBT finished the month higher 4 of 6 times, with a median return of +2.2% and an average of +1.0%. Its strongest month historically has been October at +7.1% on average, its weakest September at -5.5%.

Overnight risk is measurable too: CLBT has opened more than 2% away from the prior close in 228 of 1,504 sessions (15.2% of the time), with the largest gaps running +13.0% and -8.4%.

All figures computed from 1,505 daily closes between 2020-11-06 and 2026-11-05, split-adjusted, recomputed daily. Percentiles are against CLBT's own 6-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of CLBT's sector?

Cellebrite DI Ltd. sits in the Software sector, currently ranked 11th of 12 GICS sectors by relative-strength rotation score (lagging). Within its narrower Software industry group, CLBT ranks 13th of 15 tracked industries, lagging.

Sector rank
#11 of 12
Sector state
Lagging
Sector rotation score
18
Industry rank
#13 of 15

Options Market

What is the options market pricing for CLBT?

CallsPuts

For Cellebrite DI Ltd.'s nearest expiry (2026-11-20, 14 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.09), with at-the-money implied volatility around 73.4%. The options market is pricing roughly a ±14.3% move by that expiry — a range of about $10.59–$14.13.

Put/call ratio (2026-11-20)
0.09
ATM implied volatility
73.4%
Total open interest
1,509
Expected move by 2026-11-20
±14.3% ($10.59–$14.13)

Analyst Consensus Estimates

What do analysts expect CLBT to earn?

Analysts expect Cellebrite DI Ltd. to earn $0.55 per share in the fiscal year ending Dec 2026 and $0.59 in the fiscal year ending Dec 2028, from 2 estimates. These are analyst forecasts, not company guidance, and later years rest on fewer analysts.

Quarter endingEPS estimateEPS rangeEPS analystsRevenue estimateRevenue analysts
Sep 2026$0.16$0.14 to $0.178$146M8
Dec 2026$0.18$0.16 to $0.198$151M8
Mar 2027$0.11$0.11 to $0.112~$138M-
Jun 2027$0.12$0.11 to $0.122~$151M-
Sep 2027$0.14$0.12 to $0.152~$176M-
Fiscal year endingEPS estimateEPS rangeEPS analystsRevenue estimateRevenue analysts
Dec 2026$0.55$0.42 to $0.598$557M8
Dec 2027$0.65$0.54 to $0.738$641M8
Dec 2028$0.59$0.53 to $0.652~$741M-

Revenue marked ~ is our calculation from the EPS estimate, not analyst consensus.

Analyst Rating Changes

Are analysts turning bullish or bearish on CLBT?

DA Davidson most recently reiterated its rating on Cellebrite DI Ltd. to Buy on Sep 15, 2026 with a price target of $15. Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
DA Davidson: Buy
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Sep 15, 2026DA DavidsonMaintainedBuy$15
Aug 14, 2026Lake StreetMaintainedBuy$21 → $15
Aug 14, 2026JP MorganMaintainedOverweight$20 → $16
Aug 14, 2026DA DavidsonMaintainedBuy$22 → $15
Aug 14, 2026NeedhamMaintainedBuy$15 → $13
Aug 6, 2026DA DavidsonMaintainedBuy$20 → $22
May 27, 2026DA DavidsonInitiatedBuy$20
May 15, 2026NeedhamMaintainedBuy$18 → $15
Feb 12, 2026NeedhamMaintainedBuy$24 → $18
Nov 13, 2025JP MorganMaintainedOverweight$23 → $24
Nov 13, 2025Lake StreetMaintainedBuy$22 → $23
Nov 13, 2025B of A SecuritiesMaintainedBuy$24 → $25

Corporate Stakes

Which companies own a stake in CLBT?

0.52%held by AXON

Axon Enterprise, Inc. reports a stake in Cellebrite DI Ltd. on SEC Form 13F: 1.3M shares, about 0.52% of the company, worth $19.1M at the end of Q2 2026. At today's price that stake is worth $16.3M, about 0.05% of AXON's own market value.

Holder
AXON
Shares held
1.3M
Stake
0.52%
Value
$19.1M
HolderLast quarterShares% of CLBTValue at filingValue nowChange
Axon Enterprise, Inc. AXONUnchanged1.3M0.52%$19.1M$16.3M-15.0%

Form 13F lists US-listed shares held at quarter-end and is filed up to 45 days later. Stakes in private companies are not on it. Value now and Change put those same shares, adjusted for any stock split, at today's price against their reported quarter-end value, so they do not reflect buying or selling since.

News & sentiment

What is the news saying about CLBT?

CLBT rose 10.7% over the month to Nov 6. Daily news tone ranged from 43 to 80 and read 50 on Nov 6.

Daily close and news tone, Oct 6 to Nov 6
$11$12$13Oct 6Oct 7Oct 8Oct 9Oct 12Oct 13Oct 14Oct 15Oct 16Oct 19Oct 20: tone 48Oct 21: tone 80Oct 22Oct 23Oct 26Oct 27Oct 28Oct 29Oct 30: tone 43Nov 2Nov 3: tone 50Nov 4Nov 5: tone 56Nov 6: tone 50Oct 6News toneNov 6123
  1. Oct 14 -4.8%
  2. Oct 15 +5.1%
  3. Nov 3 +5.4%
Latest stories naming Cellebrite DI

Technical analysis

How strong is CLBT's momentum right now?

On the daily chart CLBT ranks at the 9th percentile for momentum against 1,060 stocks and ETFs, a bearish reading.

Momentum rank by timeframe0 = weakest, 100 = strongest
See what drives the rankThe inputs behind each timeframe's momentum rank, plus RSI, stochastics, Bollinger Bands and moving averages. Free with an account.

Institutional ownership

Are big funds buying or selling CLBT?

31 of the 62 tracked managers added to CLBT in their latest 13F and 26 trimmed. Together they own 8.5% of the company, worth $276.6M. Citigroup and Bank of New York Mellon alone hold 2.1%.

31adding26trimming5unchanged
Largest holders by stake, latest 13FBar = share of CLBT
  1. 1Citigroup Inc1.29%
    $36.5M positionNew position last quarter
  2. 2Bank of New York Mellon Corp0.82%
    $23.3M positionAdded 18.6% last quarter
  3. 3Capital International Investors0.82%
    $30.1M positionTrimmed 9.5% last quarter
  4. 4Orbis Allan Gray Ltd0.68%
    $24.9M positionAdded 154.7% last quarter
  5. 5Principal Financial Group Inc0.47%
    $13.4M positionTrimmed 22.9% last quarter
  6. 6Select Equity Group, L.P.0.44%
    $16.1M positionAdded 37.5% last quarter
  7. 7State Street Corp0.43%
    $15.7M positionAdded 5.6% last quarter
  8. 8Royal Bank of Canada0.41%
    $15.0M positionTrimmed 0.0% last quarter
  9. 9King Luther Capital Management Corp0.33%
    $9.3M positionAdded 28.6% last quarter
  10. 10HRT Financial LP0.30%
    $11.1K positionAdded 53.5% last quarter
Full holdings history

Discover more

How has CLBT done against its peers?

Over the six months to Nov 6, CLBT returned −6.3%. Of the 15 related stocks and ETFs, 10 did better, led by SNOW at +98.5%.

Change since May 6, through Nov 6
−100%0%+100%+200%May 6JunJulAugSepOctNov 6SNOW +98.5%CLBT −6.3%ORCL −40.2%